IP Library Granted Patent US 9,988,604
Granted Patent B2
US 9,988,604 · App. 14/807,348 · Granted Jun 5, 2018

Cell compositions derived from dedifferentiated reprogrammed cells

Inventors: Alan D. Agulnick (San Digeo, CA); Olivia Kelly (San Diego, CA); Yuki Ohi (La Jolla, CA); Allan Robins (Athens, GA); Thomas Schulz (Athens, GA)
Assignee: ViaCyte, Inc.
C12N5/0676A61K35/39C07K14/62C12P21/00C12N2500/25C12N2501/11C12N2501/115C12N2501/117C12N2501/16C12N2501/195C12N2501/385C12N2501/41C12N2501/415C12N2501/727C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,988,604
App. No.
14/807,348
Granted
Jun 5, 2018
Kind
B2
Abstract

Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.

Claims (10)

1. A method for producing insulin, said method comprising the steps of:

a. contacting dedifferentiated genetically reprogrammed cells in vitro with a first medium comprising an agent that activates a TGFβ receptor family member;

b. culturing, in vitro, the cells of step (a) in a second medium lacking the agent that activates a TGFβ receptor family member, thereby generating foregut endoderm cells;

c. contacting the foregut endoderm cells of step (b) with an ERBB receptor tyrosine kinase activating agent, thereby generating a cell population comprising endocrine cell and non-endocrine cell subpopulations; and

d. maturing the cell subpopulations of step (c) in vivo, thereby obtaining insulin secreting cells, wherein the insulin secreting cells secrete insulin in response to glucose stimulation.

2. The method of claim 1 , wherein the non-endocrine cells are CHGA negative (CHGA−) cells.

3. The method of claim 1 , wherein the endocrine cells are CHGA positive (CHGA+) cells.

4. The method of claim 1 , wherein the CHGA negative (CHGA−) cells further express NKX6.1.

5. The method of claim 1 , further comprising contacting the foregut endoderm cells with an effective amount of a rho-kinase inhibitor.

6. The method of claim 5 , wherein the rho-kinase inhibitor is selected from the group consisting of Y-27632, Fasudil, H-1152P, Wf-536, Y-30141, antisense nucleic acids for ROCK, RNA interference inducing nucleic acid, competitive peptides, antagonist peptides, inhibitory antibodies, antibody-ScFV fragments, dominant negative variants, derivatives thereof and expression vectors thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2015
From: KELLY, OLIVIA; AGULNICK, ALAN D.; OHI, YUKI; ROBINS, ALLAN; SCHULZ, THOMAS
To: VIACYTE, INC.
Reel/Frame 037320/0310 →
Continuity (5)
Continuation PCTUS2014015156 · Feb 6, 2014
Continuation 13761078 · Feb 6, 2013
Continuation In Part 12765714 · Apr 22, 2010
Provisional Application 61171759 · Apr 22, 2009
Related Publication 20160194372A1 · Jul 7, 2016